Developing antibody-delivered protein degraders to treat cancer
Some disease-driving proteins lack the binding pockets that conventional small-molecule inhibitors need. Protein degraders offer a way to remove these proteins, but selective delivery into target cells remains a challenge, with implications for off-target toxicity.
3C Therapeutics is developing cancer treatments that use antibodies to deliver protein degraders into selected cells. Its modular TriCore platform is designed to remove disease-driving proteins, with an initial focus on aggressive solid tumors.
What stands out about 3C Therapeutics
Licensed modular degrader-antibody conjugate technology jointly developed by UBC and iProgen; agreement completed in June 2025.
Reports in vitro validation of target engagement and degradation efficiency for its modular degrader-antibody conjugate platform.
Launched a collaboration with Variational AI to design ligands for TriCore; 3C handles degrader development and biological evaluation.
Recognized by UBC among its fall 2025 spin-offs, with Chemistry professor David Perrin named as the founding team.
The founding UBC-iProgen research that produced its licensed DAC technology received support from Canada's NSERC.
Co-founder Daniel Wattier previously co-founded and led Valocor Therapeutics through its strategic merger with Dermira.
Co-founder David Perrin is a UBC chemistry professor with over 20 years in medicinal chemistry and more than 120 publications.
Co-founder David Perrin previously co-founded Alpha-9 Oncology, a radiopharmaceutical company spun out of UBC and BC Cancer.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.